Ro lists its weight-loss membership at $45 for the first month and $145 a month after that. It bills the medication separately [1]. For Eli Lilly’s Foundayo, the lowest dose costs $149 a month, “additional membership fees apply” [2].
On those two numbers, the membership is 49.3% of a patient’s monthly bill ($145 of $294). That is our calculation, and it points to the core of Ro’s model. The drug price comes from the manufacturer. The fee comes from Ro.
Hims & Hers shows what happens to a telehealth company that sells more branded drug and keeps no separate fee layer. Its Q2 2026 revenue rose 38.2%. Its gross profit rose 15.5%. Its gross margin fell from 76% to 64% [3]. This article uses public filings, company releases, and patent records to test how telehealth prescribing makes money, and what protects it.
The Short Answer: What Ro Sells and Who Sets the Drug Price
What does Ro actually sell to a GLP-1 patient?
Ro sells access to a care pathway. The Ro Body membership covers provider visits, messaging, coaching, an insurance concierge, and Quest lab testing when a provider orders it [1]. The membership is cash-pay only. The medication is a separate charge [1].
Who sets the price of the GLP-1 drug on Ro?
The manufacturer does. Ro says its cash prices match LillyDirect, NovoCare, and TrumpRx [1]. Lilly publishes the Foundayo self-pay price of $149 a month for the lowest dose [4]. Ro adds its fee on top of that price.
The Findings That Matter
Membership is 49.3% of the monthly bill for the lowest-dose Foundayo plan on Ro: $145 of $294 (calculated from [1] and [2]).
Hims & Hers grew Q2 2026 revenue 38.2% and gross profit 15.5%. Its gross profit per subscriber stayed near $58 to $59 a month (calculated from [3]).
Self-pay patients are about 35% of US injectable Wegovy sales, up from roughly 10% to 15% a year earlier, according to Novo Nordisk’s Q2 2026 call [5].
The semaglutide compound patent, US 8,129,343, expires December 5, 2031 after a 1,040-day extension [6]. Mylan asked a court in March 2026 to enter judgment that its generic Wegovy infringes it [7].
FDA posted more than 100 warning and untitled letters on September 16, 2025. Most went to marketers of compounded GLP-1 drugs, including two to Hims & Hers [8].
Sacra estimates Ro reached $598 million in annualized revenue in 2024. Ro is private and does not publish audited figures [9].
Methodology: What We Analyzed and What We Could Not
What data did we use?
We used five record types. They are Ro’s pricing page and press releases, Hims & Hers’ Q2 2026 Form 8-K, Novo Nordisk and Eli Lilly statements, FDA enforcement postings, and patent-term records. The time period runs from March 2021 to October 9, 2026.
How we calculated derived figures
Each ratio uses figures printed in the cited source. Membership share equals membership fee divided by membership plus drug price. Hims marketing ratio equals marketing expense divided by gross profit. Gross profit per subscriber equals reported monthly revenue per average subscriber times gross margin. We label every calculated figure as analysis.
Limits of private-company data
Ro does not publish gross margin, customer acquisition cost, or retention. Revenue figures for Ro are third-party estimates. Valuation figures come from funding announcements and aggregators, and they conflict in places. We state each conflict where it appears.
Why Ro’s price points need a date
Ro changes its prices often. Its own pricing page showed $45 and $145 when we reviewed it [1]. Some third-party trackers report newer figures of $39 and $149. Check Ro’s page before you quote any fee.
Who Is Ro? Company Timeline and Size
How did Ro grow from Roman to a GLP-1 platform?
Date
Event
Source
2017
Ro starts as Roman, a men’s health brand
[9]
March 23, 2021
$500 million Series D at a $5 billion valuation
[10]
May 2021
Acquires Modern Fertility; reported at about $225 million (Axios estimate)
[11], [12]
February 2022
$150 million round at a $7 billion valuation (Sacra); other aggregators list $125 million at $6.8 billion
[9]
April 2025
First direct integration with Novo Nordisk
[15]
January 5, 2026
Launches the Wegovy pill on day one
[15]
April 9, 2026
Adds Lilly’s Foundayo
[2]
Ro also lists the Workpath acquisition and a Quest Diagnostics lab partnership in its press archive [13]. These deals gave Ro labs and in-home care. They explain why Ro calls itself a vertically integrated platform.
How big is Ro? Revenue and valuation estimates
Metric
Figure
Type
Source
2020 revenue
$230 million
Reported by trade press
[11]
2023 revenue
$360 million
Estimate
[9]
2024 annualized revenue
$598 million
Estimate
[9]
Last priced round
$7 billion (Feb. 2022)
Reported
[9]
Secondary-market valuation, May 2026
$2.0 billion
Third-party estimate
[14]
Why the Sacra figures do not reconcile
Sacra puts GLP-1 revenue at about $370 million in 2024 and at about 40% of revenue by the end of 2024 [9]. $370 million is 62% of $598 million. The two figures use different bases, and public data cannot reconcile them. Treat the mix estimates as directional.
What the $2.0 billion secondary estimate means
TrueUp shows a $2.0 billion secondary estimate dated May 5, 2026, which is 71% below the $7 billion round [14]. The estimate comes from a third-party data source. Ro has not confirmed it. We include it only to show that private valuation marks differ widely.
How Does the Ro Body Membership Work? The Anatomy of a Monthly Bill
What does a cash-paying patient pay each month?
Scenario
Drug
Membership
Total
Membership share
Source
Foundayo, lowest dose, month 2 onward
$149
$145
$294
49.3%
[1], [2]
Wegovy pen, new-patient offer (May 2025), month 1
$199
$45
$244
18.4%
[17]
Wegovy pen at a $349 cash price, month 2 onward (assumed)
$349
$145
$494
29.4%
[1], [24]
The $349 figure is the Novo cash price reported for existing patients in November 2025 [24]. We assume Ro bills the same price, because Ro says it matches NovoCare [1]. Shares are our analysis.
Annual membership cost
A patient who stays 12 months pays $45 plus 11 times $145, which equals $1,640 in membership fees (our calculation from [1]).
What did Ro change in 2026?
On March 31, 2026, Ro said patients could save up to $1,200 a year on the Wegovy pen and $600 a year on the Wegovy pill through Novo’s new subscription pricing [16]. The savings come from Novo’s price. The membership fee did not change in that release.
Why Is Drug Margin No Longer Where Telehealth Makes Money? The Hims & Hers Comparison
Hims & Hers is public, so its numbers show what a branded GLP-1 shift does to a telehealth income statement. In March 2026 Hims broadened its branded weight-loss assortment [25]. The next quarter shows the result.
What did Hims & Hers report for Q2 2026?
Metric
Q2 2025
Q2 2026
Change
Revenue
$544.8M
$753.2M
+38.2%
Cost of revenue
$128.6M
$272.4M
+111.8%
Gross profit
$416.2M
$480.8M
+15.5%
Gross margin
76%
64%
-12 points
Marketing expense
$217.9M
$262.2M
+20.4%
Marketing as share of gross profit (analysis)
52.3%
54.5%
+2.2 points
Income (loss) from operations
$26.7M
($97.2M)
n/a
Monthly revenue per average subscriber
$76
$92
+21%
Source for all rows except the analysis row: Hims & Hers Form 8-K, August 10, 2026 [3].
Gross profit per subscriber stayed flat
Revenue per subscriber rose $16 a month. Gross profit per subscriber did not move much. We multiply revenue per subscriber by gross margin. The result is about $58 in Q2 2025 and about $59 in Q2 2026 (analysis from rounded inputs in [3]). Hims added revenue. It did not add profit per subscriber.
How does this compare with Ro’s fee layer?
Ro does not publish margins, so we cannot make a like-for-like comparison. We can say what structure it chose. Ro’s price page separates a fixed membership from a drug price that the manufacturer controls [1]. When the drug price changes, the fee stays the same. That structure shields the fee from drug-price swings. It does not shield Ro from competition on the fee itself.
Compounded vs. Branded GLP-1s: What Changed Between 2024 and 2026
Novo opens Wegovy to telehealth partners at $499 a month; Hims lists $599
[18]
June 2025
Novo ends its Hims partnership over compounding concerns; keeps Ro and LifeMD
[19]
September 16, 2025
FDA posts more than 100 warning and untitled letters; two go to Hims
[8]
February 5, 2026
TrumpRx launches
[22]
February 20, 2026 (public March 3)
FDA sends 30 more warning letters to telehealth firms
[20]
March 2026
Hims and Novo announce a branded partnership; Hims stops most compounded marketing
[21]
What did the September 2025 FDA letters say?
FDA said the marketing of compounded semaglutide by these companies was illegal. The letters were nearly identical [8]. Our sources do not list Ro among the recipients.
Why did FDA send a second wave in 2026?
The agency said the new letters extend the September crackdown. Its commissioner linked the pledge to Hims’ attempt to market a compounded Wegovy pill [20].
Why did Novo end its Hims partnership and keep Ro?
Novo said it acted on concerns about knockoff compounded GLP-1 drugs. It stated that it was encouraged by its collaborations with Ro and LifeMD [19]. The two companies reunited under a branded deal in March 2026 [21]. Ro’s position was not a bet on compounding at any point in the sources we reviewed. Its releases describe FDA-approved drugs [15][16].
Why Do Novo Nordisk and Eli Lilly Want Telehealth Partners?
How fast is the self-pay channel growing?
Novo Nordisk said self-pay patients now make up about 35% of US injectable Wegovy sales, compared with roughly 10% to 15% a year ago [5].
That is a rise of roughly 2.3 to 3.5 times in one year (our calculation). Novo also said the Wegovy pill reached 267,000 weekly prescriptions as of July 17, 2026. About 80% of pill users are new to GLP-1 treatment, and pill prescriptions remain self-pay [5]. In December 2025 a Novo executive told Reuters that the self-pay share of US Wegovy prescriptions had jumped from about 5% to double digits that year [23].
What did Lilly do with Foundayo?
FDA approved Foundayo (orforglipron) on April 1, 2026 [29]. Lilly launched it on April 9 through LillyDirect and telehealth providers, with a $149 self-pay price at the lowest dose [4]. Ro listed it the same day [2]. Lilly said about 35% of new Zepbound prescriptions came through self-pay in late 2025, according to eMarketer [24].
What this means for brand manufacturers
Manufacturers want cash-pay volume without the insurance fight. Telehealth partners supply patient acquisition, prescriber capacity, and follow-up. In return, manufacturers give partners a fixed price. Ro’s fee is paid by the patient, not by the manufacturer, so the manufacturer controls the drug price and Ro controls the fee.
Original Framework: Three Operating Models in Telehealth Prescribing
This is an original classification. It is not an industry standard. We built it from the filings and releases cited above.
Which model earns money from the drug, and which earns it from the patient relationship?
Type 1: Margin on the drug
The telehealth company earns most of its profit from the product it sells. Hims & Hers’ 76% gross margin in Q2 2025, while it sold compounded semaglutide, fits this type [3][18]. The model is exposed to enforcement and to manufacturer pricing.
Type 2: Fee on the relationship
The company passes the drug through at the manufacturer’s price and charges a membership. Ro’s published price structure fits this type [1]. The model is exposed to fee comparison and to manufacturer channel decisions.
Type 3: Manufacturer direct
The manufacturer sells to the patient through its own pharmacy. LillyDirect and NovoCare are examples [4][18]. The telehealth company is optional here. This model sets the price ceiling for the other two.
What Does the Super Bowl Bet Imply About Ro’s Marketing Spend?
What did Ro disclose about the campaign?
Ro ran its first Super Bowl ad on February 8, 2026, starring Serena Williams, under the “Healthier on Ro” campaign [26][27]. A Ro executive acknowledged the investment was substantial, but we found no disclosed amount [26]. Williams is married to a Ro board member and investor [26]. The ad claims 34 pounds lost and cholesterol down 30% [27].
What does Hims’ marketing ratio suggest?
At Hims, marketing took 54.5% of gross profit in Q2 2026 [3]. The ratio shows how much of each gross dollar a scaled telehealth brand spends to acquire the next subscriber. Ro is private, so we cannot compute its ratio. Sacra flags brand spend as a risk to Ro’s margins if it does not lower blended acquisition cost [9].
The Patent Clock Behind Ro’s Product Line
When does the semaglutide compound patent expire?
US 8,129,343 expires December 5, 2031 [6]. Its pre-extension date was January 29, 2029. The Patent Office added 1,040 days [6]. Ozempic was approved on December 5, 2017 [6]. The extended date falls exactly 14 years after approval. That matches the 14-year cap on patent-term extension in 35 U.S.C. § 156 [30]. This comparison is our analysis.
Has anyone broken the ‘343 patent?
A 2023 inter partes review petition by Mylan against the ‘343 patent failed [28]. On March 12, 2026, Novo and Mylan asked a Delaware court to enter judgment that Mylan’s generic Wegovy infringes the patent. Such a judgment would block the copy until at least December 2031 [7]. From today, that date is about 1,884 days away, or 5.2 years (our calculation).
What if generic semaglutide arrives sooner or at a lower price?
This is a scenario, not a forecast. Assume Ro keeps a $145 fee. Assume a generic semaglutide costs $75 a month. The membership would be 65.9% of a $220 bill. A fixed fee grows as a share of the bill when the drug gets cheaper. Patients then compare the fee with the drug price more closely.
The Canadian precedent
Health Canada approved the first generic semaglutide on April 28, 2026, and Apotex announced a launch on May 14, 2026 [6]. Canada has different patent and data-protection history, so the date has no US meaning.
Tirzepatide Paragraph IV activity
The RX Index reports from FDA’s September 14, 2026 Paragraph IV list that the first challenges to Mounjaro and Zepbound were dated May 13, 2026 [6]. We did not verify the FDA list directly. A challenge is not a launch.
How does DrugPatentWatch fit into this analysis?
DrugPatentWatch tracks Orange Book patent listings, Paragraph IV filings, and litigation for drugs such as semaglutide. Patent dates in this article come from the sources listed below. Confirm them in the Orange Book or in DrugPatentWatch before you rely on them for a decision.
What Could Break Ro’s Model? Risk Analysis
Manufacturer concentration risk
Ro’s branded GLP-1 access depends on Novo and Lilly. Novo cut off Hims in 2025 [19]. The same lever could be pulled on any partner. Sacra lists channel dependence as a primary risk for Ro [9].
Price compression risk
Novo’s cash price fell from $499 to $349 for existing patients in November 2025 [24]. Lower drug prices help patients. They also make the $145 fee more visible.
Evidence and outcomes risk
Ro reports that patients on its platform lost an average of 16.6% of body weight over 68 weeks [15]. Sacra reports 655 semaglutide patients, with 95.4% losing at least 5% [9]. The data are company-published and observational. They have no control group. Use them as real-world context, not as proof of effect.
Coverage risk
Among 100,000 users of Ro’s insurance checker, 45% lacked coverage for either GLP-1 and 26.7% had coverage for both [9]. Ro says the checker has helped over 2 million people understand coverage [2]. If employers or Medicare pay for more of the drug, a cash-only membership reaches fewer patients.
What This Means for Different Readers
What this means for generic challengers
Telehealth channels are a possible route to patients on the day a generic launches. A generic entrant should expect fee-based platforms to pass through the lowest manufacturer price, not to bid for the generic.
What this means for competitive intelligence teams
Track four items: manufacturer price changes, FDA enforcement letters, partner terminations, and patent rulings. The Hims case shows that one partner decision can reorder a market in one quarter [19][21].
Key Takeaways
Ro charges a fee for care. The manufacturer sets the drug price [1][4].
On a lowest-dose Foundayo plan, membership is 49.3% of the monthly bill (analysis).
Hims grew revenue 38.2% but gross profit only 15.5%, and gross profit per subscriber stayed near $58 to $59 (analysis of [3]).
Novo says self-pay is about 35% of US injectable Wegovy sales [5].
FDA enforcement and Novo’s partner choices pushed telehealth toward branded drugs [8][19][20].
The semaglutide compound patent runs to December 5, 2031 [6].
Ro is private. Its revenue and valuation figures are estimates [9][14].
FAQ
How much does Ro cost each month for a GLP-1?
Ro lists its Body membership at $45 for the first month and $145 a month afterward, with medication billed separately [1]. Foundayo starts at $149 a month at the lowest dose [2]. Prices change, so check Ro’s page.
Is Ro a pharmacy?
Ro says it is the only company offering nationwide telehealth, labs, and pharmacy services [16]. Sacra reports that manufacturers and CenterWell Pharmacy handle sourcing and fulfillment for branded GLP-1 programs [9].
Does Ro sell compounded semaglutide?
Every GLP-1 named in the Ro releases we reviewed is FDA-approved [2][15][16]. We did not find a Ro statement about compounded sales.
Why did Novo end its Hims & Hers partnership but keep Ro?
Novo cited concerns over compounded knockoffs and said it was encouraged by its Ro and LifeMD collaborations [19]. Novo and Hims announced a new branded deal in March 2026 [21].
What is Ro’s annual revenue?
Ro does not publish it. Sacra estimates $598 million in annualized revenue for 2024, up 66% from $360 million in 2023 [9]. For scale, Hims reported $753.2 million for Q2 2026 alone [3].
What is Ro worth?
The last priced round valued Ro at $7 billion in February 2022, according to Sacra [9]. One third-party estimate dated May 2026 shows $2.0 billion in the secondary market [14]. Ro has not confirmed either current value.
When could generic Wegovy launch in the US?
Not before December 2031 if the court enters the requested judgment on the ‘343 patent [7]. Later patents could extend that date [6]. Canada’s generic approval in April 2026 does not change US dates [6].
Does the Ro membership cover the medication?
No. Ro bills the medication separately from the membership, and the membership is cash-pay only [1].
How is Ro’s model different from Hims & Hers’ model?
Both now sell branded GLP-1s. Hims reported its gross margin fell to 64% as branded mix grew [3][25]. Ro does not report margins, but it publishes a separate fee and drug price [1].
Are Ro’s weight-loss results reliable?
They are real-world data published by the company: a 16.6% average loss over 68 weeks [15]. They come from observation, with no control group, so they cannot show cause [9].
References
Ro. (n.d.). How much does the Ro Body membership cost? Ro. https://www.ro.co/weight-loss/pricing/ (accessed October 9, 2026)
Ro. (2026, April 9). Ro offers Eli Lilly’s Foundayo, the newest GLP-1 innovation. https://ro.co/press/foundayo/
Hims & Hers Health, Inc. (2026, August 10). Form 8-K: Second quarter 2026 financial results. U.S. Securities and Exchange Commission. https://www.sec.gov/Archives/edgar/data/0001773751/000177375126000161/hims-20260630x8xkearningsr.htm
Eli Lilly and Company. (2026, April 9). Foundayo (orforglipron), Lilly’s new oral GLP-1 pill for weight loss, now available in the U.S. PR Newswire. https://lilly.gcs-web.com/node/54111/pdf
The Markets Daily. (2026, August 8). Novo Nordisk A/S Q2 earnings call highlights. https://www.themarketsdaily.com/2026/08/08/novo-nordisk-a-s-q2-earnings-call-highlights.html
The RX Index. (2026, September 25). GLP-1 drug patent expiration tracker: U.S. patents and generic status. https://therxindex.com/research/glp-1-patent-expiration-dates/
Bloomberg Law. (2026, March 12). Novo, Mylan seek judgment on key Wegovy patent before trial. https://news.bloomberglaw.com/ip-law/novo-mylan-seek-judgment-on-key-wegovy-patent-before-trial
Regulatory Affairs Professionals Society. (2025, September 16). FDA posts more than 100 warning and untitled letters in ad crackdown. https://www.raps.org/resource/fda-posts-more-than-100-warning-and-untitled-lette.html
Sacra. (n.d.). Ro revenue, valuation and funding. https://sacra.com/c/ro/
Latham & Watkins LLP. (2021, March 23). Latham & Watkins advises Ro in its US$500 million Series D financing. https://www.lw.com/en/news/2021/03/latham-watkins-advises-ro-series-d-financing
Beauty Matter. (2021, May 21). Ro acquires Modern Fertility in $225 million deal. https://www.beautymatter.com/articles/ro-acquires-modern-fertility-in-225-million-deal
MobiHealthNews. (2021, May). D2C virtual care company Ro strengthens reproductive offerings with Modern Fertility acquisition. https://www.mobihealthnews.com/news/d2c-virtual-care-company-ro-strengthens-reproductive-offerings-modern-fertility-acquisition
Ro. (n.d.). Press releases. https://ro.co/press/
TrueUp. (2026). Ro company profile. https://trueup.io/co/ro
Ro. (2026, January 5). Ro launches Wegovy pill through integration with Novo Nordisk. https://ro.co/press/wegovy-pill/
Ro. (2026, March 31). Ro helps patients save up to $1,200 per year on Wegovy through collaboration with Novo Nordisk. https://ro.co/press/wegovy-savings-options/
Ro. (2025, May 22). Ro introduces one-month $199 Wegovy new patient offer and discounted Body membership. https://ro.co/press/wegovy-promo/
CNBC / NBC Los Angeles. (2025). Novo Nordisk opens weight loss drug Wegovy to telehealth; Hims & Hers shares rocket 23%. https://www.nbclosangeles.com/news/business/money-report/novo-nordisk-opens-weight-loss-drug-wegovy-to-hims-hers-ro-and-life-md-telehealth/3688787/
Fierce Healthcare. (2025). Novo Nordisk inks partnership with WeightWatchers to broaden Wegovy access. https://www.fiercehealthcare.com/health-tech/novo-nordisk-inks-partnership-weightwatchers-broaden-wegovy-access
Fierce Pharma. (2026, March). FDA ramps up crackdown on GLP-1 drug compounding with fresh batch of 30 warning letters. https://www.fiercepharma.com/pharma/fda-ramps-crackdown-glp-1-drug-compounders-fresh-batch-30-warning-letters
Frier Levitt. (2026). From crackdown to collaboration: FDA warning letters and the Hims-Novo Nordisk deal. https://www.frierlevitt.com/articles/fda-warning-letters-hims-novo-nordisk-compounded-glp1/
Spencer Fane LLP. (2026). FDA and Novo Nordisk warn of GLP-1 telehealth compounding take down: What’s next. https://www.spencerfane.com/insight/fda-and-novo-nordisk-warn-of-glp-1-telehealth-compounding-take-down-whats-next/
Reuters. (2025, December 23). Novo’s newly approved Wegovy pill to test out demand from cash-paying consumers. https://finance.yahoo.com/news/novos-wegovy-pill-test-demand-060639758.html
EMARKETER. (2025, November 18). Novo Nordisk bets on lower GLP-1 prices to counter Eli Lilly’s Zepbound surge. https://www.emarketer.com/topics/category/self-pay
MarketBeat. (2026, August 10). Hims & Hers Health Q2 earnings call highlights. https://www.marketbeat.com/instant-alerts/hims-hers-health-q2-earnings-call-highlights-2026-08-10/
Cassius Life. (2026). Serena Williams’ Super Bowl GLP-1 ad for Ro. https://cassiuslife.com/1374208/serena-williams-super-bowl-glp-1-ad-ro/
FirstMark Capital. (2026, February 9). Ro debuts first-ever Super Bowl commercial. https://firstmark.com/story/ro-debuts-first-ever-super-bowl-commercial/
Markman Advisors. (2025, February 7). What is the patent landscape for Novo Nordisk’s semaglutide products? https://www.markmanadvisors.com/blog/2025/2/7/what-is-the-patent-landscape-for-novo-nordisks-semaglutide-products-ozempic-wegovy-and-rybelsus
Fierce Healthcare. (2026, April). Eli Lilly launches oral GLP-1 drug across US through LillyDirect, telehealth providers. https://www.fiercehealthcare.com/telehealth/eli-lillys-launches-oral-glp-1-drug-across-us-through-lilly-direct-telehealth-providers
Patent term extension, 35 U.S.C. § 156. U.S. Code. https://uscode.house.gov/view.xhtml?edition=prelim&num=0&req=granuleid%3AUSC-prelim-title35-section156
